Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

聯康集團
Uni-Bio Science

UNI-BIO SCIENCE GROUP LIMITED
聯康生物科技集團有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 0690)

GRANT OF SHARE OPTIONS

This announcement is made pursuant to Rule 17.06A of the Listing Rules.

GRANT OF OPTIONS

The Board announces that on 24 June 2026, the Company has granted to four eligible participants, subject to their acceptance, share options to subscribe for an aggregate of 300,000,000 Shares (upon exercise in full and subject to adjustment in accordance with the Share Option Scheme) under the Share Option Scheme as follows:

Name of Grantee	Capacity	Number of Shares to be issued upon exercise of the Options granted to such Grantee in full
Mr. Leung Kingsley	Chairman of the Board and executive Director	90,000,000
Mr. Zhao Zhi Gang	Chief executive officer and executive Director	90,000,000
Dr. Wen Yalei	Chief operating officer and executive Director	60,000,000
Mr. Cheng Yu-Jen	Chief business officer	60,000,000
		300,000,000

TERMS AND CONDITIONS OF THE OPTIONS

Save for the maximum number of Shares that the relevant Grantee may subscribe for pursuant to the exercise of the Options granted to such Grantee, the terms and conditions of all Options conditionally granted on 24 June 2026 are the same, a summary of the terms and conditions of such grant are set out below:

Date of grant	:	24 June 2026
Exercise price of Options granted	:	HK$0.09 per Share, representing the highest of: (i) the closing price of HK$0.08 per Share as stated in the Stock Exchange's daily quotation sheet on the Date of Grant; (ii) the average closing price of HK$0.09 per Share as stated in the Stock Exchange's daily quotation sheets for the five consecutive business days immediately preceding the Date of Grant; and (iii) the nominal value of a Share on the Date of Grant.
Exercise period of the Options	:	Subject to the fulfilment of the exercise conditions as detailed below, the Grantee may exercise the Options (to the extent vested) up to the tenth anniversary of the date of grant. Any unexercised portion will automatically lapse upon expiry of the 10-year term.
Vesting schedule of the Options	:	Vesting will occur in accordance with the following schedule: (1) one-third of the Options (subject to adjustment(s)) shall be vested to Grantee on the first anniversary of the Date of Grant. The date on which such vesting occurs is hereinafter referred to as the First Vesting Date; (2) one-third of the Options as at the Date of Grant (subject to adjustment(s)) shall be vested on the first anniversary of the First Vesting Date; and (3) the remaining one-third of the Options as at the Date of Grant (subject to adjustment(s)) shall be vested on the second anniversary of the First Vesting Date.
Consideration for the grant of the Options	:	HK$1.00 to be paid by each Grantee upon acceptance of the Options granted.

Exercise Conditions	:	The exercise of the Options under the grant is subject to the fulfilment of the conditions specified below: (1) the Company records audited consolidated revenue of not less than HK$1,000,000,000 in its audited consolidated financial statements for any full financial year ending on or before 31 December 2028; and (2) in the same financial year, the Company records audited consolidated profit for the year of not less than HK$100,000,000 in its audited consolidated financial statements for that financial year. If the conditions are not met in any financial year on or before the date immediately following the publication of the Company's preliminary announcement for FY2028, all Options (whether or not vested) shall not be exercisable and the Options granted hereunder shall lapse automatically.
Clawback mechanism	:	There is no clawback mechanism attached to the share options. Without prejudice to the terms and conditions of the Share Option Scheme, the Options granted to a Grantee shall lapse if such Grantee ceases to be a qualifying participant of the Share Option Scheme by reason of termination of employment for, among other matters, persistent or serious misconduct, or has committed any act of bankruptcy, or has become insolvent, or has made any arrangement or composition with his creditors generally, or has been convicted of any criminal offence. The Remuneration Committee of the Board is of the view that clawback mechanism is not necessary for the grant of the Options to the Grantees who are all employees of the Group as the lapse of the Options in various scenarios have already been provided for under the Share Option Scheme which could adequately safeguard the Company's interests.
Financial assistance	:	No financial assistance shall be provided by the Group to the Grantees to facilitate the purchase/subscription of Shares under the Share Option Scheme.

As at the Date of Grant, the Company had 5,971,228,147 Shares in issue.

REASONS FOR AND BENEFITS OF THE GRANTS

The grant of the Options aims to align the interests of the Grantees with those of the Group through ownership of Shares and incentivise the Grantees to remain with the Group, and to motivate and encourage them to work towards enhancing the Group's corporate value and achieving the long-term objectives for the benefit of the Group as a whole.

LISTING RULES IMPLICATIONS

Pursuant to Rule 17.04(1) of the Listing Rules, any grant of Options to a Director, chief executive or substantial Shareholder under the Share Option Scheme must be approved by independent non-executive Directors. The independent non-executive Directors have approved such of the grant, in accordance with the said Rule 17.04(1).

Pursuant to Rule 17.03D of the Listing Rules and the terms of the Share Option Scheme, if the grant of Options to a Grantee would result in the Shares in issue and to be issued under all Options granted to such Grantee by the Company during the 12-month period up to and including the date of grant (excluding any Options which have lapsed under the terms of the Share Option Scheme) in excess of 1% of the relevant class of Shares of the Company in issue ("**1% Individual Limit**"), then the Company must convene a separate general meeting to seek Shareholders' approval (at which the Grantee and its close associates or, in the case of the Grantee who is a connected person, its associates must abstain from voting). In addition, pursuant to Rule 17.04(2) of the Listing Rules, if the grant of Options to a Director (other than an independent non-executive director) of the Company or any of its associates would result in the total number of Shares of the Company in issue and to be issued under all Options granted (excluding Options or awards lapsed under the terms of the Share Option Scheme) during the 12-month period up to the date of grant of Options to such person exceeding in aggregate 0.1% of the Shares of the relevant class in issue ("**0.1% Limit**"), then such proposed grant of Options shall be approved by the Shareholders in a general meeting in the manner described in Rule 17.04(4).

Save as disclosed above, as at the date of this announcement, none of the Grantees is (i) a Director, chief executive or substantial Shareholder of the Company or an associate (as defined in the Listing Rules) of any of the abovementioned; (ii) a participant whose Options granted and to be granted under Rule 17.03D of the Listing Rules exceed the 1% Individual Limit; or (iii) a participant, being a related entity, or a service provider and the Shares under the Options granted or to be granted to him/her is in excess of 0.1% of the issued Shares within any 12-month period.

GENERAL INFORMATION

No option has been granted by the Company under the Share Option Scheme within the 12-month period prior to the Date of Grant.

After the above grant of the Options, 297,122,814 Shares underlying the options under the Share Option Scheme will be available for future grants under the existing scheme mandate limit.

A circular containing, among other things, (i) further details of the grant of the Options to individual Grantees; and (ii) a notice of the general meeting will be despatched to the Shareholders under the Listing Rules in due course.

DEFINITIONS

Terms or expressions used in this announcement shall, unless the context otherwise requires, have the meanings ascribed to them below:

"associate(s)"	has the meaning ascribed thereto in the Listing Rules
"Board"	the board of Directors
"Company"	Uni-Bio Science Group Limited 聯康生物科技集團有限公司*, a company incorporated in the Cayman Islands with limited liability and the issued Shares of which are listed on Stock Exchange
"Date of Grant"	24 June 2026
"Director(s)"	the director(s) of the Company
"FY2028"	the financial year ending 31 December 2028
"Grantees"	collectively, Mr. Leung Kingsley, Mr. Zhao Zhi Gang, Dr. Wen Yalei and Mr. Cheng Yu-Jen, and each a "Grantee"
"Group"	the Company and its subsidiaries
"Hong Kong"	the Hong Kong Special Administrative Region of the PRC
"HK$"	Hong Kong dollars, the lawful currency of Hong Kong
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange
"Option(s)"	any option(s) to be granted to Grantee(s) to subscribe for new Share(s) under the Share Option Scheme
"Share(s)"	ordinary share(s) of HK$0.01 each in the share capital of the Company
"Share Option Scheme"	the share option scheme of the Company approved and adopted by the Company at the extraordinary general meeting of the Company held on 26 May 2026

"Shareholder(s)"	holder(s) of the Share(s)
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"%"	per cent.

On behalf of the Board
Uni-Bio Science Group Limited
Kingsley Leung
Chairman

Hong Kong, 24 June 2026

As at the date of this announcement, the Board comprises four executive Directors, namely, Mr. Kingsley Leung (Chairman), Mr. Chen Dawei (Vice-Chairman), Mr. Zhao Zhi Gang (Chief executive) and Dr. Wen Yalei (Chief Operating Officer); two non-executive Directors, Mr. Yau Kwok Wing Tony and Ms. Zhang Qing; and three independent non-executive Directors, namely, Mr. Chow Kai Ming, Mr. Ren Qimin and Mr. Ma Qingshan.

* *For identification purposes only*